Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human)
Urethra Cancer
Explore 16 assets in Urethra Cancer →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Altor BioScience
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01326871CT.gov A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urethra Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human) (this asset) | Altor BioScience | P1/2 | CCC · 52 |
| Vinflunine | Dr Anders Ullén | P2 | BB |
| Carboplatin | Jonsson Comprehensive Cancer Center | P2 | BB |
| Sorafenib | Dr Anders Ullén | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P1/2 | B |
| Pembrolizumab | Emory University | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Emory University | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
+21 more in the Urethra Cancer cohort
Other indications for Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P2 | CCC · 53 |
| Bladder Transitional Cell Carcinoma | — | P1/2 | CCC · 52 |
| Malignant Renal Pelvis Neoplasm | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human) in Urethra Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tcr-alphabeta-receptor-anti-human-p53-protein-synthetic-human-single-chain-precursor-fusion-protein-with-interleukin-2-human-urethra-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →